Aim: We compared the efficacy and safety of ozenoxacin (a new nonfluorinated quinolone) 1% cream with placebo in the treatment of impetigo.

Patients & Methods: In a randomized, double-blind, multicenter study, patients received ozenoxacin cream or placebo cream twice daily for 5 days (a third group received retapamulin 1% ointment as a control). Clinical, microbiological and laboratory evaluations were performed during follow-up (over 2 weeks).

Results: Ozenoxacin was superior to placebo (success rate 34.8 vs 19.2%; p = 0.003). Microbiological success was 70.8% for ozenoxacin and 38.2% for placebo after 3-4 days and 79.2% versus 56.6% after 6-7 days. Ozenoxacin produced more rapid microbiological clearance than retapamulin. All treatments were well tolerated.

Conclusion: Ozenoxacin 1% cream was effective and safe in the treatment of impetigo.

Download full-text PDF

Source
http://dx.doi.org/10.2217/fmb.14.78DOI Listing

Publication Analysis

Top Keywords

ozenoxacin cream
12
treatment impetigo
8
cream placebo
8
ozenoxacin
7
cream treatment
4
impetigo multicenter
4
multicenter randomized
4
randomized placebo-
4
placebo- retapamulin-controlled
4
retapamulin-controlled clinical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!